Prospective study of Candida species in patients at a comprehensive cancer center

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 7, 2001, Pages 2129-2133

  Safdar, A ^a   Chaturvedi, V ^a   Cross, E W ^a   Park, S ^a   Bernard, E M ^a   Armstrong, D ^a   Perlin, D S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; CANCER CENTER; CANDIDA; CANDIDIASIS; FEMALE; FUNGUS IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROPHYLAXIS; UNITED STATES;

ANTIFUNGAL AGENTS; CANDIDA; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 0034949280     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.7.2129-2133.2001     Document Type: Article

References (45)

1. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches
2. Problems in management of opportunistic fungal diseases
3. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450
4. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System
5. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System
6. Strain variation among and antifungal susceptibilities of isolates of Candida krusei
7. The emergence of fungi as major hospital pathogens
8. Fungal infections in AIDS patients
9. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans
10. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
11. Fluconazole resistance in Candida glabrata
12. Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy
13. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole
14. Epidemiology of nosocomial fungal infections, with emphasis on Candida species
15. Azole drug resistance in yeasts
16. Risk factors for candidemia in cancer patients: A case-control study
17. Fungemia caused by "nonpathogenic" yeasts
18. Candida colonization and systemic infection in neutropenic patients. A retrospective study
19. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality
20. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
21. Fluconazole and Candida krusei fungemia
22. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission
23. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program
24. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
25. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
26. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates
27. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
28. National epidemiology of mycoses survey: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species
29. Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions
30. Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model
31. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths
32. Resistance of Candida species to fluconazole
33. The value of fungal surveillance cultures as predictors of systemic fungal infections
34. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
35. Antifungal drug resistance in pathogenic fungi
36. Nosocomial fungal infections: Candidemia
37. Nosocomial candidemia: Risk factors and attributable mortality
38. Hospital-acquired candidemia. The attributable mortality and excess length of stay
39. Importance of Candida species other than C. albicans as pathogens in oncology patients
40. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy
41. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
42. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
43. Nosocomial Candida. Epidemiology, transmission, and prevention